| ID | Short Name | Description and NCI 60 Expression Level (protein or mRNA) |
Pathway | Weizmann Gene Card |
| 1 | ABL | ABL (proto-oncogene tyrosine-protein kinase) | Abl1 is a tyrosine-protein kinase and a homolog of the v-abl Abelson murine leukemia viral oncogene. | ABL |
| 2 | ACK2 | ACK2 (tyrosine-protein kinase) | null | null |
| 3 | ALK | ALK (anaplastic lymphoma tyrosine kinase Ki-1) | Anaplastic lymphoma kinase (Alk) is involved in a common translocation in non-Hodgkin's lymphoma. | ALK |
| 4 | ARG | ARG (tyrosine-protein kinase) | Arg is a tyrosine-protein kinase and a homolog of the v-abl Abelson murine leukemia viral oncogene. | ABL2 |
| 5 | AXL | AXL (receptor tyrosine kinase) | Axl is a receptor tyrosine kinase and may be involved in the protection of neurons from apoptosis. | AXL |
| 6 | Bad | Bad (BCL2-antagonist of cell death) | BAD promotes cell death by competing for the binding to bcl-x(l) and bcl-2. | BAD |
| 7 | Bas | BAS (protein tyrosine phosphatase) | PTP-BAS is a non-receptor-type protein tyrosine phosphatase. | PTPN13 |
| 8 | Bax 1 | Bax (BCL2-associated X protein) 1 | BAX accelerates apoptosis by binding to, and antagonizing the apoptosis repressor bcl-2. BAX is mutated in certain tumors. | BAX |
| 9 | Bax 2 | Bax (BCL2-associated X protein) 2 | BAX accelerates apoptosis by binding to, and antagonizing the apoptosis repressor bcl-2. BAX is mutated in certain tumors. | BAX |
| 10 | Bcl-2 | Bcl-2 (Apoptosis regulator) | null | BCL2 |
| 11 | Bcl-xl | Bcl-xl (BCL2-like 1) | Bcl-xl is a dominant regulator of apoptotic cell death. | BCL2L1 |
| 12 | Bcl-xl basal level | Bcl-xl (BCL2-like 1)basal levels | Bcl-xL may be dominant regulator of apoptotic cell death, with the long form displaying cell death repressor activity. | BCL2L1 |
| 13 | BDP1 | BDP1 (tyrosine phosphatase) | Brain Derived Phosphatase (BDP1) is a protein tyrosine phosphatase, with greatest homology with members of the PTP-PEST family. | PTPN18 |
| 14 | Blk | Blk (B lymphoid tyrosine kinase) | B lymphoid tyrosine kinase (Blk) is a member of the Src family. | BLK |
| 15 | BMX | BMX (non-receptor tyrosine kinase) | Bmx (Bone marrow kinase, X-linked) is a cytoplasmic tyrosine-protein kinase with a possible role in the growth and differentiation of hematopoietic cells. | BMX |
| 16 | BRK | BRK (Protein tyrosine kinase 6) | Brk (protein tyrosine kinase 6) is a non-receptor type protein tyrosine kinase. | PTK6 |
| 17 | BTK | BTK (Bruton agammaglobulinemia tyrosine kinase) | Bruton agammaglobulinemia tyrosine kinase may have a role in B-cell development. Defects in BTK are the cause of X-linked agammaglobulinemia type 1. | BTK |
| 18 | c-iap1 | c-iap1 (mRNA level apoptosis inhibitor 2) | c-iap1 is an inhibitor of apoptosis. | BIRC2 |
| 20 | c-iap2 | c-iap2 (mRNA level apoptosis inhibitor 1) | c-iap2 is an inhibitor of apoptosis. | BIRC3 |
| 21 | c-Myc | c-Myc (basic helix-loop-helix transcription factor family) | Myc is a transcription factor. Overexpression of c-myc has been implicated in the etiology of a variety of hematopoietic tumors. | MYC |
| 22 | Carcinoembryonic antigen | Carcinoembryonic antigen | The solid tumor lines were characterized individually using immunocytochemical techniques to determine their relative degrees of representativity for the subpanels within which they are grouped. | CEACAM5 |
| 23 | CCK4 | CCK4 (tyrosine kinase) | Human colon carcinoma kinase-4, CCK4 (PTK7), may be a tumor progession marker. | PTK7 |
| 24 | CD45 | CD45 (protein tyrosine phosphatase, receptor type) | Leukocyte antigen CD45 is a receptor type protein tyrosine phosphatase with a possible role in T-cell activation. | PTPRC |
| 25 | cIAP1 | cIAP1 (apoptosis inhibitor) | cIAP1 is an inhibitor of apoptosis that may interact with TNF receptor associated factors 1 and 2 (TRAF1 and TRAF2). | BIRC2 |
| 26 | Class-3 aldehyde dehydrogenase | Class-3 aldehyde dehydrogenase | Aldehyde dehydrogenase detoxifies a class of nitrogen mustards, the oxazaphosphorines. It is present in many normal cells, but absent from certain tumor cells. | ALDH3A1 |
| 27 | Class-I aldehyde dehydrogenase | Class-I aldehyde dehydrogenase | Aldehyde dehydrogenase detoxifies a class of nitrogen mustards, the oxazaphosphorines. It is present in many normal cells, but absent from certain tumor cells. | ALDH1A1 |
| 28 | CSF1R | CSF1R (csf-1receptor, a protein tyrosine-kinase) | Colony stimulating factor 1 receptor is a protein tyrosine-kinase transmembrane receptor. |
CSF1R |
| 29 | CSK | CSK (c-src tyrosine kinase) | c-src tyrosine kinase phosphorylates a tyrosine residue on c-src which acts as a negative regulatory site. | CSK |
| 30 | CTK | CTK (megakaryocyte-associated tyrosine kinase) | Megakaryocyte-associated tyrosine kinase belongs to the CSK subfamily. | MATK |
| 31 | Cytochrome B5 reductase | Cytochrome B5 reductase | Many antitumor drugs require metabolic activation, catalyzed by reductase enzymes, to exert their cytotoxic or cytostatic effects. | DIA1 |
| 32 | Cytochrome P450 7-Benzyloxyresorufin dealkylation | Cytochrome P450 7-Benzyloxyresorufin dealkylation (Waxman) | Many antitumor drugs either undergo P450 enzyme-catalyzed metabolism leading to drug inactivation, or in some cases require metabolic activation catalyzed by P450 enzymes, to exert their cytotoxic or cytostatic effects | null |
| 33 | Cytochrome P450 7-Ethoxycoumarin 0-deethylase | Cytochrome P450 7-Ethoxycoumarin 0-deethylase (Waxman) | Many antitumor drugs either undergo P450 enzyme-catalyzed metabolism leading to drug inactivation, or in some cases require metabolic activation catalyzed by P450 enzymes, to exert their cytotoxic or cytostatic effects. | null |
| 34 | Cytochrome P450 7-ethoxyresorufin deethylase | Cytochrome P450 7-ethoxyresorufin deethylase (Waxman) | Many antitumor drugs either undergo P450 enzyme-catalyzed metabolism leading to drug inactivation, or in some cases require metabolic activation catalyzed by P450 enzymes, to exert their cytotoxic or cytostatic effects. | null |
| 35 | Cytochrome P450 Coumarin hydroxylase | Cytochrome P450 Coumarin hydroxylase (Waxman) | Many antitumor drugs either undergo P450 enzyme-catalyzed metabolism leading to drug inactivation, or in some cases require metabolic activation catalyzed by P450 enzymes, to exert their cytotoxic or cytostatic effects. | null |
| 36 | Cytochrome P450 reductase | Cytochrome P450 reductase | Many antitumor drugs require metabolic activation, catalyzed by reductase enzymes, to exert their cytotoxic or cytostatic effects. | POR |
| 37 | DDR | DDR (discoidin domain receptor tyrosine kinase) | Discoidin domain receptor tyrosine kinases may be activated by collagen. | DDR1 DDR2 |
| 38 | DEP-1 | DEP-1 (protein tyrosine phosphatase, receptor type) | Dep-1 is a receptor-type protein-tyrosine phosphatase which may be involved in inhibition of cell growth. | PTPRJ |
| 39 | Desmin 56kD | Desmin 56kD | The solid tumor lines were characterized individually using immunocytochemical techniques to determine their relative degrees of representativity for the subpanels within which they are grouped. | DES |
| 40 | Dihydrodiol dehydrogenase | Dihydrodiol dehydrogenase | Dihydrodiol dehydrogenase catalyzes the detoxification of polycyclic aromatic hydrocarbons and organochloride pesticides. |
AKR1C1 AKR1C2 AKR1C3 AKR1C4 |
| 41 | Dihydropyrimidine dehydrogenase | Dihydropyrimidine dehydrogenase | Dihydropyrimidine dehydrogenase is involved in pyrimidine catabolism. It catalyzes the reduction of uracil and thymine and may also be involved the degradation of the chemotherapeutic drug 5-fluorouracil. | DPYD |
| 42 | DT diaphorase | DT diaphorase | Many antitumor drugs require metabolic activation, catalyzed by reductase enzymes, to exert their cytotoxic or cytostatic effects. | NQO1 |
| 43 | EphA1 | EphA1 (ephrin receptor, tyrosine kinase) | EphA1 is a receptor for members of the ephrin-a family (binds with low affinity to ephrin-a1) and is a protein tyrosine kinase. | EPHA1 |
| 44 | EphA2 | EphA2 (ephrin receptor, tyrosine kinase) | EphA2 is a receptor for members of the ephrin-a family (binds to ephrin-a1, -a3, -a4 and -a5) and is a protein tyrosine kinase. | EPHA2 |
| 45 | EphA3 | EphA3 (ephrin receptor, tyrosine kinase) | EphA3 is a receptor for members of the ephrin-a family (binds to ephrin-a2, -a3, -a4 and -a5) and is a protein tyrosine kinase. | EPHA3 |
| 46 | EphA4 | EphA4 (ephrin receptor, tyrosine kinase) | EphA4 is a receptor for members of the ephrin-a family (binds to ephrin-a1, -a4 and -a5, and more poorly to ephrin-a2 and a-3) and is a protein tyrosine kinase. | EPHA4 |
| 47 | EphA5 | EphA5 (ephrin receptor, tyrosine kinase) | EphA5 is a receptor for members of the ephrin-a family (binds to ephrin-a1, -a2, -a3, -a4 and -a5) and is a protein tyrosine kinase. | EPHA5 |
| 48 | EPhA6 | EphA6 (ephrin receptor, tyrosine kinase) | EphA6 is a receptor for members of the ephrin-a family. | null |
| 49 | EphA7 | EphA7 (ephrin receptor, tyrosine kinase) | EphA7 is a receptor for members of the ephrin-a family (binds to ephrin-a1, -a2, -a3, -a4 and -a5) and is a protein tyrosine kinase. | EPHA7 |
| 50 | EphA8 | EphA8 (ephrin receptor, tyrosine kinase) | EphA8 is a receptor for members of the ephrin-a family and is a protein tyrosine kinase | EPHA8 |
| 51 | EphB1 | EphB1 (ephrin receptor, tyrosine kinase) | EphB1 is a receptor for members of the ephrin-b family (binds to ephrin-b1, -b2 and -b3) and is a protein tyrosine kinase. | EPHB1 |
| 52 | EphB2 | EphB2 (ephrin receptor, tyrosine kinase) | EphB2 is a receptor for members of the ephrin-b family and is a protein tyrosine kinase. | EPHB2 |
| 53 | EphB3 | EphB3 (ephrin receptor, tyrosine kinase) | EphB3 is a receptor for members of the ephrin-b family and is a protein tyrosine kinase. | EPHB3 |
| 54 | EphB4 | EphB4 (ephrin receptor, tyrosine kinase) | EphB4 is a receptor for members of the ephrin-b family (binds to ephrin-b2) and is a protein tyrosine kinase. | EPHB4 |
| 55 | EphB5 | EphB5 (ephrin receptor, tyrosine kinase) | EphB5 is a receptor for members of the ephrin-b family and is a protein tyrosine kinase. | null |
| 56 | EGFR | Epidermal growth factor receptor -1 | The EGF receptor may mediate the biological signal of EGF, and also of TGF-alpha, amphiregulin, heparin-binding EGF, gp30 and vaccinia virus growth factor. | EGFR |
| 57 | EGFR-2 | Epidermal growth factor receptor -2 | The EGF receptor may mediate the biological signal of EGF, and also of TGF-alpha, amphiregulin, heparin-binding EGF, gp30 and vaccinia virus growth factor. | EGFR |
| 58 | ErbB2 | ErbB2 (receptor protein-tyrosine kinase) | ErbB2 (also known as Her2 or Neu) is a membrane tyrosine kinase, and a potential receptor for neuregulins and gp30. The gene is amplified in some tumors, particularly breast tumors. | ERBB2 |
| 59 | ESP | ESP (protein tyrosine phosphatase) | null | null |
| 60 | FAK | FAK (focal adhesion tyrosine kinase) | Focal adhesion kinase 1 is a protein tyrosine kinase that is widely expressed in T and B lymphocytes. | PTK2 |
| 61 | FAP-1 | FAP-1 (Fas-associated phosphatase-1) | Fas-associated phosphatase-1 is a negative regulator of Fas-mediated apoptosis. | PTPN13 |
| 62 | FER | FER (proto-oncogene tyrosine-protein kinase) | Fer is a non-receptor protein tyrosine kinase. | FER |
| 63 | FES | FES (proto-oncogene tyrosine-protein kinase) | FES is a proto-oncogene tyrosine-protein kinase and a homolog of feline sarcoma (Snyder-Theilen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fps) oncogenes. | FES |
| 64 | FGF2 | FGF2 (fibroblast growth factor 2, basic) | FGF2 binds heparin and may be an angiogenic agent in vivo and a mitogen for a variety of cell types. | FGF2 |
| 65 | FGFR2 | FGFR2 (fibroblast growth factor receptor 2) | FGFR2 is a receptor for acidic and basic fibroblast growth factors and a protein tyrosine kinase. | FGFR2 |
| 66 | Fgr | Fgr (proto-oncogene tyrosine-protein kinase) | Fgr is a proto-oncogene tyrosine-protein kinase and a member of the Src family. | FGR |
| 67 | Fgfr-1 | Fibroblast growth factor receptor 1 (receptor tyrosine kinase) -1 | Fgfr1 is a receptor for basic fibroblast growth factor and is a tyrosine kinase. | FGFR1 |
| 68 | Fgfr-1 | Fibroblast growth factor receptor 1 (receptor tyrosine kinase) -2 | Fgfr1 is a receptor for basic fibroblast growth factor and is a tyrosine kinase. | FGFR1 |
| 69 | Fgfr-2 | Fibroblast growth factor receptor 2 | FGFR2 is a receptor for acidic and basic fibroblast growth factors and a protein tyrosine kinase. |
FGFR2 |
| 70 | Fgfr-3 | Fibroblast growth factor receptor 3 | Fgfr3 belongs to the fibroblast growth factor receptor family. | FGFR3 |
| 71 | Fgfr-4 | Fibroblast growth factor receptor 4 | Fgfr4 is a receptor for acidic fibroblast growth factor. | FGFR4 |
| 72 | FLK1 | FLK1 (receptor for vegf or vegf-c, tyrosine kinase) | FLK1 is a receptor for vascular endothelial growth factor (VEGF or VEGF-c) and a protein tyrosine kinase. | KDR |
| 73 | FLK2 | FLK2 (receptor tyrosine kinase) | FLT3 is a receptor for the FL cytokine and a protein tyrosine kinase. | FLT3 |
| 74 | FLT1 | FLT1 (receptor for vegf and plgf, tyrosine kinase) | FLT1 is a receptor for vascular endothelial growth factor (VEGF and PLGF) and a protein tyrosine kinase. | FLT1 |
| 75 | FLT4 | FLT4 (receptor for vegf-c, tyrosine kinase) | FLT4 is a receptor for vascular endothelial growth factor (VEGF-C) and a protein tyrosine kinase. | FLT4 |
| 76 | FRK | FRK (fyn-related tyrosine kinase) | Fyn-related kinase belongs to the src family of protein tyrosine kinases. | FRK |
| 77 | Fyn | Fyn (proto-oncogene tyrosine-protein kinase) | Fyn is a proto-oncogene tyrosine-protein kinase and a member of the Src family. | FYN |
| 78 | G1 Arrest after 630 Gy X-Ray | G1 Arrest after 630 Gy X-Ray | The ability of cells to arrest in the G1 phase of the cell cycle following X-irradiation is dependent on a functional checkpoint. | null |
| 79 | Gadd34 | Gadd34 (DNA-damage-inducible transcript) basal levels | GADD34 is a DNA damage-inducible factor whose expression may lead to apoptosis. | PPP1R15A |
| 80 | Gadd45 | Gadd45 (DNA-damage-inducible transcript 1) mRNA induction after X-ray | Gadd45 binds to proliferating cell nuclear antigen (might affect PCNA interaction with some CDK (cell division protein kinase) complexes; stimulates DNA excision repair in vitro and inhibits entry of cells into S phase. | GADD45A |
| 81 | Gadd45 basal level | Gadd45 (DNA-damage-inducible transcript 1)basal levels | Gadd45 binds to proliferating cell nuclear antigen (might affect PCNA interaction with some CDK (cell division protein kinase) complexes; stimulates DNA excision repair in vitro and inhibits entry of cells into S phase. |
GADD45A |
| 82 | Gamma Glu Cys synthetase | Gamma Glu Cys synthetase | Glutamate--cysteine ligase performs the first and rate-limiting step in de novo glutathione biosynthesis. Glutathione prevents cellular free radical damage. |
GCLC GCLM |
| 83 | Gamma Glu transpeptidase | Gamma Glu transpeptidase | Gamma-glutamyltranspeptidase plays a key role in the gamma-glutamyl cycle, a pathway for the synthesis and degradation of glutathione. Glutathione prevents cellular free radical damage. |
GGT1 GGT2 GGT3 |
| 84 | GLEPP1 | GLEPP1 (protein tyrosine phosphatase, receptor type) | GLEPP1 is a receptor type protein tyrosine phosphatase. | PTPRO |
| 85 | GFAP | Glial fibrillary acidic protein (GFAP) 56kD | The solid tumor lines were characterized individually using immunocytochemical techniques to determine their relative degrees of representativity for the subpanels within which they are grouped. | GFAP |
| 86 | Glutathione s-transferase mu | Glutathione s-transferase mu | Glutathione S-transferases prevent cellular free radical damage. |
GSTM1 GSTM2 GSTM3 GSTM4 GSTM5 |
| 87 | Glutathione s-transferase pi-1 | Glutathione s-transferase pi-1 | Glutathione S-transferases prevent cellular free radical damage. | GSTP1 |
| 88 | Glutathione s-transferase pi-2 | Glutathione s-transferase pi-2 | Glutathione S-transferases prevent cellular free radical damage. | GSTP1 |
| 89 | Glyoxylase I | Glyoxylase I | Glyoxylase I catalyzes the formation of s-lactoylglutathione. | GLO1 |
| 90 | HA2 | HA2 (protein-tyrosine phosphatase) | HA2 is a protein tyrosine phosphatase. | null |
| 91 | Hck | Hck (hemopoietic cell tyrosine kinase) | Hemopoietic cell kinase (Hck) is a protein tyrosine kinase and a member of the Src family. | HCK |
| 92 | Her2 | Her2 (Receptor protein-tyrosine kinase Erbb-2) | ErbB2 (also known as Her2 or Neu) is a membrane tyrosine kinase, and a potential receptor for neuregulins and gp30. The gene is amplified in some tumors, particularly breast tumors. | ERBB2 |
| 93 | Her3 | HER3 (erbb-3 receptor protein-tyrosine kinase) | ErbB3 is a tyrosine kinase receptor and may be activated by neuregulins and NTAK. It is overexpressed in some breast tumors. | ERBB3 |
| 94 | Her4 | Her4 (Receptor protein-tyrosine kinase Erbb-4) | ErbB4 is a tyrosine kinase receptor and may be activated neuregulins, NRG- 2, NRG-3, heparin-binding EGF-like growth factor, betacellulin and NTAK. | ERBB4 |
| 95 | hMLH1 | hMLH1 (DNA mismatch repair protein) | Mlh1 is involved in the repair of mismatches in DNA. Defects in Mlh1 have been associated with familial hereditary nonpolyposis colon cancer (HNPCC). | MLH1 |
| 96 | hMLH2 | hMLH2 (DNA mismatch repair protein) | Msh2 is involved in the repair of mismatches in DNA. Defects in Msh2 have been associated with familial hereditary nonpolyposis colon cancer (HNPCC). | MSH2 |
| 97 | HSC | HSC (tyrosine kinase) | null | null |
| 98 | IA2 | IA2 (protein tyrosine phosphatase, receptor type) | IA2 is a protein-tyrosine phosphatase with a possible role in neuroendocrine secretory processes. | PTPRN |
| 99 | IAR | IAR (protein tyrosine phosphatase, receptor type) | IAR is a protein-tyrosine phosphatase. | PTPRN2 |
| 100 | IGF1R | IGF1R (insulin-like growth factor 1 receptor, tyrosine kinase) | Insulin-like growth factor 1 receptor is a protein tyrosine kinase and binds IGF I with a high affinity and IGF II with a lower affinity | IGF1R |
| 101 | INSR | INSR (insulin receptor, tyrosine kinase) | The insulin receptor is a protein tyrosine kinase. | INSR |
| 102 | IRR | IRR (insulin receptor-related receptor, tyrosine kinase) | INSRR is a receptor tyrosine kinase related to the insulin receptor. | INSRR |
| 103 | ITK | ITK (IL2-inducible T-cell tyrosine kinase) | IL2-inducible T-cell kinase is a protein tyrosine kinase expressed mainly in T-cells and NK cells. | ITK |
| 104 | JAK-1 | JAK1 (Janus kinase 1, protein tyrosine kinase) | Janus kinase 1 is a non-receptor-type protein tyrosine kinase and is a kinase partner for the interleukin (IL)-2 receptor. | JAK1 |
| 105 | JAK-2 | JAK2 (Janus kinase 2, protein tyrosine kinase) | Janus kinase 2 is a non-receptor-type protein tyrosine kinase and may be involved in interleukin 3 signal transduction. | JAK2 |
| 106 | KDR | KDR (receptor tyrosine kinase) | KDR is a receptor for vascular endothelial growth factor (VEGF or VEGF-C) and a protein tyrosine kinase. | KDR |
| 107 | KIT | KIT (receptor for stem cell factor, tyrosine kinase) | Kit is a receptor for stem cell factor (mast cell growth factor) and a tyrosine-protein kinase. It is a homolog of the v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene. | KIT |
| 108 | LAR | LAR (protein tyrosine phosphatase, receptor type) | LAR is a receptor-type protein tyrosine phosphatase. | PTPRF |
| 109 | LC | LC (protein tyrosine phosphatase) | LC-PTP is a non-receptor-type protein tyrosine phosphatase. | PTPN7 |
| 110 | Lck | Lck (proto-oncogene tyrosine-protein kinase) | Lymphocyte-specific protein tyrosine kinase (Lck) is a proto-oncogene and a member of the Src family. | LCK |
| 111 | LRP | LRP (Drug efflux pump) | null | null |
| 112 | LTK | LTK (leukocyte tyrosine kinase receptor) | Leukocyte tyrosine kinase belongs to the insulin receptor family. | LTK |
| 113 | Lyn | Lyn (tyrosine-protein kinase) | Lyn is a proto-oncogene tyrosine-protein kinase and a member of the Src family. | LYN |
| 114 | MDM2 | MDM2 (p53 binding protein) | Mdm2 binds to p53 and can downregulate p53 function. | MDM2 |
| 115 | MDM2 basal levels | MDM2 (p53-binding protein) basal levels | Mdm2 binds to p53 protein forming a tight complex. Can inhibit p53-mediated transactivation. | MDM2 |
| 116 | Mdr1 | Mdr1 (Multidrug resistance gene) | Drug resistance is a major reason for the failure of cancer chemotherapy. One widely studied mechanism of drug resistance involves the ability of P-glycoprotein to act as a drug efflux pump. | ABCB1 |
| 117 | MEG | MEG (megakaryocyte protein tyrosine phosphatase) | PTP-MEG is a non-receptor-type protein tyrosine phosphatase. | PTPN4 |
| 118 | MEG-2 | Meg2 (protein-tyrosine phosphatase) | PTP-Meg2 is a non-receptor-type protein tyrosine phosphatase. | PTPN9 |
| 119 | MER | MER (proto-oncogene tyrosine kinase) | c-mer proto-oncogene tyrosine kinase may bind the vitamin K-dependent protein growth-arrest-specific gene 6 (Gas6). | MERTK |
| 120 | MET | MET (hepatocyte growth factor receptor, tyrosine kinase) | The met proto-oncogene is a receptor for hepatocyte growth factor and is a protein tyrosine kinase. | MET |
| 121 | Metallothionein | Metallothionein (whole cell) | Because of the high cysteine content in mettalothioneins (MTs), these low molecular weight proteins bind heavy metals and protect cells against the toxicity of metals such as Cd. Previous studies have also implicated MT in resistance to some anticancer drugs and mutagens. |
MT1A MT1B MT1E MT1F MT1G MT1H MT1I MT1J MT1K MT1L MT1Q MT1S MT1X MT2A MT3 |
| 122 | metallothionein nuclear/cytoplasm ratio | metallothionein nuclear/cytoplasm ratio | null |
MT1A MT1B MT1E MT1F MT1G MT1H MT1I MT1J MT1K MT1L MT1Q MT1S MT1X MT2A MT3 |
| 123 | MGMT | MGMT (O-6-methylguanine-DNA methyltransferase) expression | O-6-methylguanine-DNA methyltransferase repairs alkylated guanines in DNA. | MGMT |
| 124 | MRP | MRP (Drug efflux pump) | Drug resistance is a major reason for the failure of cancer chemotherapy. One widely studied mechanism of drug resistance involves the ability of P-glycoprotein to act as a drug efflux pump. | ABCC1 |
| 125 | Mrp | Mrp (Multidrug resistance protein) | Drug resistance is a major reason for the failure of cancer chemotherapy. One widely studied mechanism of drug resistance involves the ability of P-glycoprotein to act as a drug efflux pump. | ABCC1 |
| 126 | MUSK | MUSK (muscle, skeletal, receptor tyrosine kinase) | MUSK is a skeletal muscle specific receptor tyrosine kinase. | MUSK |
| 127 | Mutation of N-ras, K-ras and H-ras | Mutation of N-ras, K-ras and H-ras | Activation of RAS results in the recruitment of the serine/threonine protein kinase RAF to the plasma membrane, activating a MAP kinase signal transduction cascade. |
HRAS KRAS2 NRAS |
| 128 | NADPH Cytochrome P450 reductase | NADPH Cytochrome P450 reductase (Waxman) | Many antitumor drugs either undergo P450 enzyme-catalyzed metabolism leading to drug inactivation, or in some cases require metabolic activation catalyzed by P450 enzymes, to exert their cytotoxic or cytostatic effects. | POR |
| 129 | Neurofilament 70 and 200kD | Neurofilament 70 and 200kD | The solid tumor lines were characterized individually using immunocytochemical techniques to determine their relative degrees of representativity for the subpanels within which they are grouped. |
INA NEF3 NEFH NEFL PRPH |
| 130 | Nm23 | Nm23 (protein expressed in non-metastatic cells) | Nm23 (nucleoside diphosphate kinase) was initially identified as being associated with non-metastatic cancers. Reduced levels of nm23 have been associated with poor prognosis for some types of cancer. |
NME1 NME2 NME3 NME4 NME5 |
| 131 | p-AKT | P(ser473)AKT (Dajun) | AKT is a Ser-Thr kinase important in cell signaling via the PI3K pathway, is activated by phosphorylation, and is constitutively activated in some tumors. AKT is negatively regulated by PTEN. |
AKT1 AKT2 AKT3 |
| 132 | p53 | p53 | p53 is a tumor suppressor that is responsible for inducing cell cycle arrest or apoptosis in response to cellular stress. | TP53 |
| 133 | P53 functional assay (cDNA) | P53 functional assay (cDNA) | p53 is a tumor suppressor that is responsible for inducing cell cycle arrest or apoptosis in response to cellular stress. | TP53 |
| 134 | P53 mutation (cDNA) | P53 mutation (cDNA) | p53 is a tumor suppressor that is responsible for inducing cell cycle arrest or apoptosis in response to cellular stress. | TP53 |
| 135 | P53 protein | P53 protein | p53 is a tumor suppressor that is responsible for inducing cell cycle arrest or apoptosis in response to cellular stress. | TP53 |
| 136 | PCP-2 (tyrosine kinase) | PCP-2 (tyrosine kinase) | PCP-2 is a receptor-type tyrosine phosphatase. | PTPRU |
| 137 | PDGFRa | PDGFRa (pdgf-a or pdgf-b receptor, tyrosine kinase) | Platelet-derived growth factor receptor, alpha can bind either PDGF-A or PDGF-B and is a protein tyrosine kinase. | PDGFRA |
| 138 | PDGFRb | PDGFRb (pdgf-b receptor, tyrosine kinase) | Platelet-derived growth factor receptor, beta binds specifically to PDGF-B and is a protein tyrosine kinase. | PDGFRB |
| 139 | PEST | PEST (protein-tyrosine phosphatase) | PTP-PEST is a non-receptor-type protein tyrosine phosphatase. Defects in PTP-PEST have been found in some colon cancers. | PTPN12 |
| 140 | PEZ | PEZ (protein-tyrosine phosphatase) | PEZ is a non-receptor-type protein tyrosine phosphatase. | PTPN14 |
| 141 | PTEN | PTEN (Dajun) | AKT is a Ser-Thr kinase important in cell signaling via the PI3K pathway, is activated by phosphorylation, and is constitutively activated in some tumors. AKT is negatively regulated by PTEN. | PTEN |
| 142 | PTP-1B | PTP-1B (protein tyrosine phosphatase) | PTP-1B is a non-receptor-type protein tyrosine phosphatase. | PTPN1 |
| 143 | PTP-36 | PTP-36 (protein tyrosine phosphatase) | null | null |
| 144 | PTP-a | PTP-a (protein-tyrosine phosphatase) | null | PTPRA |
| 145 | PTP-b | PTP-b (protein-tyrosine phosphatase) | null | PTPRB |
| 146 | PTP-d | PTP-d (protein-tyrosine phosphatase) | null | PTPRD |
| 147 | PTP-D1 | PTP-D1 (protein tyrosine phosphatase) | null | PTPN21 |
| 148 | PTP-e | PTP-e (protein-tyrosine phosphatase) | null | PTPRE |
| 149 | PTP-g | PTP-g (protein-tyrosine phosphatase) | null | PTPRG |
| 150 | PTP-k | PTP-k (protein-tyrosine phosphatase) | null | PTPRK |
| 151 | PTP-m | PTP-m (protein-tyrosine phosphatase) | null | PTPRM |
| 152 | PTP-s | PTP-s (protein-tyrosine phosphatase) | null | PTPRS |
| 153 | PTP-S31 | PTP-S31 (protein-tyrosine phosphatase) | null | null |
| 154 | PTP-SL | PTP-SL (protein tyrosine phosphatase, receptor type) | PTP-SL is a receptor-type protein tyrosine phosphatase. | PTPRR |
| 155 | PTP-z | PTP-z (protein-tyrosine phosphatase) | null | PTPRZ1 |
| 156 | PTP20 | PTP20 (protein-tyrosine phosphatase) | null | null |
| 157 | PYK2 | PYK2 (protein tyrosine kinase) | PYK2 is a protein tyrosine kinase. | PTK2B |
| 158 | Reduced folate carrier | Reduced folate carrier | A transporter for the uptake of folate. | SLC19A1 |
| 159 | RET | RET (proto-oncogene tyrosine-protein kinase receptor) | The ret proto-oncogene is a receptor-type protein tyrosine kinase and is associated with a number of related familial cancer syndromes. | RET |
| 160 | Rhodamine exclusion | Rhodamine exclusion (MDR activity) | Drug resistance is a major reason for the failure of cancer chemotherapy. One widely studied mechanism of drug resistance involves the ability of P-glycoprotein to act as a drug efflux pump. | null |
| 161 | RON | RON (macrophage stimulating protein receptor, tyrosine kinase) | RON is a receptor for macrophage stimulating protein (MSP) and is a protein tyrosine kinase. | MST1R |
| 162 | ROR1 | ROR1 (neurotrophic tyrosine kinase receptor-related) | Ror1 is an orphan cell surface receptor and and may be a protein tyrosine kinase. | ROR1 |
| 163 | ROR2 | ROR2 (neurotrophic tyrosine kinase receptor-related) | Ror2 may be a receptor protein tyrosine kinase. | ROR2 |
| 164 | ROS | ROS (proto-oncogene tyrosine-protein kinase) | ROS is receptor-type protein tyrosine kinase and a homolog of the v-ros avian UR2 sarcoma virus oncogene. |